Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HAS-BLED scores in predicting MACE in AF

Andrew D. Blann; Gregory Y. H. Lip

doi:10.1160/TH14-11-0932

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 113(05): 1155-1157
DOI: 10.1160/TH14-11-0932

Letters to the Editor

Schattauer GmbH

Renal, endothelial function, warfarin management, and the CHADS², CHA²DS²VASc and HAS-BLED scores in predicting MACE in AF

Andrew D. Blann

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Gregory Y. H. Lip

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Am Med Assoc 2001; 285: 2864-2870.
2 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010; 137: 263-272.
3 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 2010; 138: 1093-1100.
4 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
5 Piccini JP, Stevens SR, Chang Y. et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular AF: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF) and ATRIA (AnTicoagulation and Risk factors In AF) study cohorts. Circulation 2013; 127: 224-232.
6 Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
7 Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37: 2294-2300.
8 Suzuki M, Matsue Y, Nakamura R. et al. Improvement of HAS-BLED bleeding score predictive capability by changing the definition of renal dysfunction in Japanese AF patients on anticoagulation therapy. J Cardiol. 2014. Epub ahead of print.
9 Ammash N, Konik EA, McBane RD. et al. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Thromb Vasc Biol 2011; 31: 2760-2766.
10 Freynhofer MK, Gruber SC, Bruno V. et al. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. Int J Cardiol 2013; 168: 317-325.
11 Roldán V, Marín F, Muiña B. et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated AF patients. J Am Coll Cardiol 2011; 57: 2496-2504.
12 Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. Thromb Thrombolysis 2013; 35: 333-335.
13 Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. Thromb Thrombolysis 2011; 31: 249-258.
14 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
15 Stormorken H, Erikssen J. Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men. Thromb Haemost 1977; 38: 874-878.
16 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
17 Hylek EM, Ko D, Cove CL. Gaps in translation from trial to practice: Non-vitamin K antagonist oral anticoagluants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 11: 783-788.